Speaking at The New York Times’s DealBook Summit, Eli Lilly’s chief executive and an obesity medicine specialist discussed ...

Losing weight with anti-obesity medications (AOM) also resulted in decreased alcohol consumption for about half of the ...

The push to develop the first oral GLP-1 receptor drug for obesity is heating up, as four phase 3 drugs race to become the first approved oral treatment for obesity, Global Data reported Dec. 2. Here ...

More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...

Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.

Participants in Wegovy clinical trials were more likely to report “severe gastrointestinal adverse reactions,” the FDA's ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some individuals.

Engineers designed a new type of gastric balloon that can be inflated and deflated as needed. It could offer an alternative for people who don't want to undergo more invasive treatments such as ...

GLP-1 receptor agonists, like Ozempic and Wegovy, have been everywhere over the past few years, and research seems to be ...

Amylin analogs present a strong alternative or complement to GLP-1 receptor agonists, potentially eliciting higher-quality ...

Enveda’s pipeline is led by ENV-294, a first-in-class, oral small molecule being developed to treat atopic dermatitis and other inflammatory conditions by combining the advantages of blockbuster drugs ...